Page 99 - 83_01

Clinical Pharmacy in the Genomic Era
medical use. Indeed, it has often been demanded that in the
treatment of man …. only such agents shall be used as are
absolutely free from danger. Were one to yield to this
demand, any progress of therapeutics, in a
chemotherapeutic sense, would be altogether impossible;
for substances which are capable of freeing the living body
from an infection cannot be regarded as indifferent; there
must rather be inherent in them a certain characteristic
toxicity’ (40).
The use of medicines always involves important trade-
offs and clinical pharmacists may help their patients in
better appreciating this.
Acknowledgments: The Figures are all taken from the
author’s Genomic Medicine 101 (41).
REFERENCES
1. Serturner FW. Analyse de l'Opium. De la Morphine et
de l'Acide méconique, considérés comme parties
essentielles de l'opium. Annales de Chimie et de
Physique 1817;5:23-41.
2. Berdoe E. Paracelsus: the reformer of medicine.
Edinburgh: Royal College of Physicians of
Edinburgh; 1888.
3. Farrington B. Greek Science and its meaning for us.
London: Penguin Books; 1961.
4. Garrod AE. A Contribution to the Study of
Alkaptonuria. Med Chir Trans 1899;82:367-94.
5. Bateson W. Mendel's principles of heredity.
Cambridge: Cambridge University Press; 1909.
6. Cassidy DC. Uncertainty. The life and science of
Werner Heisenberg. New York: W.H. Freeman and
Company; 1991.
7. Kalow W. Pharmacogenetics Heredity and the
response to drugs. Philadelphia: W.B. Saunders; 1962.
8. Evans FT, Gray PW, Lehmann H, Silk E. Sensitivity
to succinylcholine in relation to serum-cholinesterase. 25. Adams J, Kauffman M. Development of the
Lancet 1952;1:1229-30.
9. Alving AS, Carson PE, Flanagan CL, Ickes CE.
Enzymatic deficiency in primaquine-sensitive
erythrocytes. Science 1956;124:484-5.
10. Alving AS, Kellermeyer RW, Tarlov A, Schrier S,
Carson PE. Biochemical and genetic aspects of
primaquine-sensitive hemolytic anemia. Ann Intern
Med 1958;49:240-8.
11. Tarlov AR, Brewer GJ, Carson PE, Alving AS.
Primaquine sensitivity. Glucose-6-phosphate
dehydrogenase deficiency: an inborn error of
metabolism of medical and biological significance.
Arch Intern Med 1962;109:209-34.
12. Motulsky AG. Drug reactions enzymes, and
biochemical genetics. J Am Med Assoc
1957;165:835-7.
13. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701
screening for hypersensitivity to abacavir. N Engl J
Med 2008;358:568-79.
14. Bell CC, Faulkner L, Martinsson K, et al. T-cells from
HLA-B*57:01+ human subjects are activated with
@Real Academia Nacional de Farmacia. Spain
abacavir through two independent pathways and
induce cell death by multiple mechanisms. Chem Res
Toxicol 2013;26:759-66.
15. Darnell J. RNA: Life's indispensable molecule. New
York: Cold Spring Harbor Laboratory Press; 2011.
16. Lynch SV, Pedersen O. The Human Intestinal
Microbiome in Health and Disease. N Engl J Med
2016;375:2369-79.
17. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics
shape the physiology and gene expression of the
active human gut microbiome. Cell 2013;152:39-50.
18. Ehrlich P. Address in Pathology, On chemiotherapy:
Delivered before the Seventeenth International
Congress of Medicine. Br Med J 1913;2:353-9.
19. Weiss B. Antisense oligodeoxynucleotides and
antisense RNA. Novel pharmacological and
therapeutic agents. New York: CRC Press; 1997.
20. Melton DA. Antisense RNA and DNA. New York:
Cold Spring Harbor Laboratory; 1988.
21. Druker BJ. David A. Karnofsky Award lecture.
Imatinib as a paradigm of targeted therapies. J Clin
Oncol 2003;21:239s-45s.
22. Driggers EM, Hale SP, Lee J, Terrett NK. The
exploration of macrocycles for drug discovery--an
underexploited structural class. Nat Rev Drug Discov
2008;7:608-24.
23. Raynal NJ, Da Costa EM, Lee JT, et al. Repositioning
Fda-Approved Drugs in Combination with Epigenetic
Drugs to Reprogram Colon Cancer Epigenome. Mol
Cancer Ther 2016.
24. Wainwright CE, Elborn JS, Ramsey BW, et al.
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis
Homozygous for Phe508del CFTR. N Engl J Med
2015;373:220-31.
proteasome inhibitor Velcade (Bortezomib). Cancer
Invest 2004;22:304-11.
26. Ward JW, Mermin JH. Simple, Effective, but Out of
Reach? Public Health Implications of HCV Drugs. N
Engl J Med 2015;373:2678-80.
27. Nathwani AC, Reiss UM, Tuddenham EG, et al.
Long-term safety and efficacy of factor IX gene
therapy in hemophilia B. N Engl J Med
2014;371:1994-2004.
28. Booth C, Gaspar HB, Thrasher AJ. Treating
Immunodeficiency through HSC Gene Therapy.
Trends Mol Med 2016;22:317-27.
29. Syed YY. Eteplirsen: First Global Approval. Drugs
2016;76:1699-704.
30. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of
infantile-onset spinal muscular atrophy with
nusinersen: a phase 2, open-label, dose-escalation
study. Lancet 2017;388:3017-26.
31. Li-Wan-Po A. Pharmacogenetics begins to deliver on
its promises. Bmj 2015;351:h5042.
99